Healthcare / Medical Instruments & SuppliesTokyo
$6660.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.2B · quality 82.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19980
P/E
227.3x
↑EV/EBITDA
16.1x
↑ROE
2.0%
↑Gross Margin
32.2%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.1%
FCF CAGR
+5.6%
FCF margin
16.0%
FCF / Net income
4.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $39.14B · net income $1.52B · FCF $6.25B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $39.14B | $39.14B | $39.10B | $38.98B | $36.78B |
| Net Income | $1.52B | $1.52B | $2.80B | $4.32B | $4.37B |
| EBITDA | $8.74B | $8.74B | $10.71B | $9.84B | $10.41B |
| EPS | — | — | 115.57 | 177.95 | 153.00 |
| Gross Margin | 32.2% | 32.2% | 33.4% | 40.4% | 41.9% |
| Operating Margin | 9.7% | 9.7% | 10.7% | 17.0% | 16.7% |
| Net Margin | 3.9% | 3.9% | 7.2% | 11.1% | 11.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.07 | 0.11 | 0.13 |
| Current Ratio | 5.34 | 5.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.25B | $6.25B | $4.32B | $7.78B | $5.30B |
| Returns | |||||
| ROE | 2.0% | 2.0% | 3.3% | 5.2% | 5.5% |
| Valuation | |||||
| P/E | 227.30 | 227.30 | 31.58 | 17.25 | 20.85 |
| EV/EBITDA | 16.09 | 16.09 | 7.00 | 6.56 | 8.34 |
| P/B | 2.00 | 2.00 | 1.03 | 0.89 | 1.14 |
| Growth & Yield | |||||
| Revenue Growth | 0.1% | 0.1% | 0.3% | 6.0% | — |
| EPS Growth | — | — | -35.1% | 16.3% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+64.7%
Start / end P/E
n/dx → n/dx
EPS bridge
115.57 → n/d
Residual
+63.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.